Dechra Pharmaceuticals マネジメント

マネジメント基準チェック /44

Dechra Pharmaceuticalsの CEO はIan Pageで、 Nov2001年に任命され、の在任期間は 21.42年です。の年間総報酬は£ 2.07Mで、 28.8%給与と71.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.36%を直接所有しており、その価値はMX$ 338.86M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と4.2年です。

主要情報

Ian Page

最高経営責任者

UK£2.1m

報酬総額

CEO給与比率	28.8%
CEO在任期間	21.4yrs
CEOの所有権	0.4%
経営陣の平均在職期間	5.8yrs
取締役会の平均在任期間	4.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Dechra Pharmaceuticals の収益と比較して、Ian Page の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m
Mar 31 2017	n/a	n/a	UK£19m
Dec 31 2016	n/a	n/a	UK£11m
Sep 30 2016	n/a	n/a	UK£12m
Jun 30 2016	UK£2m	UK£440k	UK£13m

報酬と市場: Ianの総報酬 ($USD 2.58M ) は、 MX市場 ($USD 2.38M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Ianの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ian Page (61 yo)

21.4yrs

在職期間

UK£2,073,000

報酬

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ian Page	CEO, MD & Executive Director	21.4yrs	UK£2.07m	0.36% MX$ 338.9m
Paul Sandland	CFO & Executive Director	4yrs	UK£932.00k	0.010% MX$ 9.8m
Anthony Griffin	MD of Dechra Veterinary Products for Europe & Executive Director	10.9yrs	UK£856.00k	0.033% MX$ 31.0m
Patrick Meeus	Group Scientific Officer	less than a year	データなし	データなし
Katy Clough	Group HR Director	no data	データなし	データなし
Mike Eldred	President of North America	no data	データなし	データなし
Melanie Hall	Company Secretary	5.8yrs	データなし	データなし

5.8yrs

平均在職期間

55.5yo

平均年齢

経験豊富な経営陣: DPH Nの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ian Page	CEO, MD & Executive Director	25.8yrs	UK£2.07m	0.36% MX$ 338.9m
Paul Sandland	CFO & Executive Director	3.5yrs	UK£932.00k	0.010% MX$ 9.8m
Anthony Griffin	MD of Dechra Veterinary Products for Europe & Executive Director	10.4yrs	UK£856.00k	0.033% MX$ 31.0m
Ishbel Jean Macpherson	Independent Non-Executive Director	10.2yrs	UK£83.00k	0.0059% MX$ 5.6m
Geeta Gopalan	Non-Executive Director	less than a year	データなし	データなし
Lawson MacArtney	Senior Independent Director	6.3yrs	UK£78.00k	0.0052% MX$ 4.9m
Alison Platt	Non-Executive Chairman	3.1yrs	UK£132.00k	0.0033% MX$ 3.1m
Lisa Morrison	Designated Non-Executive Director	4.2yrs	UK£72.00k	0.0012% MX$ 1.2m
John Shipsey	Non-Executive Director	less than a year	UK£5.00k	0.00053% MX$ 505.4k

4.2yrs

平均在職期間

59yo

平均年齢

経験豊富なボード: DPH Nの取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

Dechra Pharmaceuticals マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44